CONNECT WITH US
HealthTech

HealthTech

Weekly weight-loss injection combo shows promise

Medical Xpress logo

Published on

Add as a preferred source on Google
Weekly weight-loss injection combo shows promise

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

Two lower doses of CagriSema, a weekly injection combining two appetite-reducing medicines, cagrilintide and semaglutide, led to substantial weight loss in adults with obesity or with overweight and a weight-related health condition such as high blood pressure or sleep apnea, according to the REDEFINE 9 randomized controlled trial published in The Lancet Diabetes & Endocrinology journal.

The 68-week Phase IIIb trial involved 309 adults without diabetes (77% women, average age 48 years, average starting weight 109.5 kg [241 pounds]) at 24 sites in Canada, France, Germany, the U.K. and the U.S. Participants were randomly assigned to weekly injections of CagriSema at 1.7 mg of each medication (1.7 mg cagrilintide/1.7 mg semaglutide; 104 people), CagriSema at 1.0 mg of each medication (1.0 mg cagrilintide/1.0 mg semaglutide; 103 people) or placebo (102 people), alongside nutrition and physical activity counseling.

For those who remained on treatment, average weight loss at 68 weeks was 20.7% with the 1.7 mg/1.7 mg dose and 21.0% with the 1.0 mg/1.0 mg dose, compared with 2.0% with placebo. A second analysis, which included everyone regardless of whether they stopped treatment, found average weight losses of 19.4%, 18.6% and 4.6%, respectively.

7% with placebo). 4 inches) with placebo.



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.